Skip to main content

Table 3 Matrix effect, recovery, and process efficiency of AZD5305 (mean ± SD, n = 5)

From: Liquid chromatography-tandem mass spectrometry for pharmacokinetics evaluation of AZD5305, a selective PARP1 inhibitor, in mice

Nominal concentration (ng/mL)

Matrix effect (%)

Recovery (%)

Process efficiency (%)

Mouse plasma

   

AZD5305

   

 3

96.5 ± 3.43

87.1 ± 9.59

84.0 ± 3.43

 30

86.5 ± 0.906

99.5 ± 3.27

86.0 ± 0.906

 900

87.1 ± 1.29

99.7 ± 1.79

86.8 ± 1.29

Olaparib (IS, 300 ng/mL)

94.6 ± 5.15

98.3 ± 4.83

90.4 ± 4.19